|

Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis

RECRUITINGSponsored by Centre Georges Francois Leclerc
Actively Recruiting
SponsorCentre Georges Francois Leclerc
Started2026-11-01
Est. completion2030-11-01
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

The objective of this prospective multicenter study is to evaluate whether the analysis of immunological biomarkers present in circulating extracellular vesicles is associated with the response to anti-PD-1/PD-L1 treatments in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) or unresectable melanoma. Patients will receive standard-of-care treatment and will be followed according to routine clinical practice. The study involves the collection of four study-specific blood samples at different time points during follow-up, as well as the collection of standard immunohistochemistry results, thoraco-abdomino-pelvic CT scans, and tumor DNA genotyping analyses performed as part of routine care. The study aims to determine: * whether baseline biomarkers in extracellular vesicles are associated with response to anti-PD-1/PD-L1 treatment, * how these biomarkers change over the course of treatment, and * to provide exploratory data for the development of predictive immunological response signatures.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age ≥18 years.
* Histologically confirmed diagnosis of non-small cell lung cancer (NSCLC) or locally advanced/metastatic unresectable melanoma.
* Patient scheduled to initiate anti-PD-(L)1 therapy, either as monotherapy or in combination (other immune checkpoint inhibitors, chemotherapy, etc.).
* Baseline tumor assessment performed within 28 days prior to enrollment (CT scan of thorax, abdomen, and pelvis) with at least one measurable lesion according to RECIST 1.1 criteria.
* Life expectancy \>6 months.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at enrollment.
* Patient able to provide informed consent and comply with study procedures.
* Patient covered by a social security system or equivalent.

Exclusion Criteria:

* Prior treatment with immunotherapy.
* Presence of EGFR or ALK mutation (applicable only to the lung cohort).
* Presence of another synchronous malignancy.
* Diagnosis of uveal melanoma.
* Treatment with systemic immunosuppressants, including within 28 days prior to enrollment, or corticosteroids \>10 mg/day, including within 14 days prior to enrollment.
* Disease not measurable according to RECIST 1.1 criteria.
* Positive serology for HIV, HBV, or HCV.
* Pregnant or breastfeeding women.
* Inability to comply with study follow-up and visits for geographic, social, or psychological reasons.
* Individuals deprived of liberty or under legal guardianship (including curatorship).

Conditions4

CancerLung CancerMelanoma (Skin Cancer)Non Small Cell Lung Cancer

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.